|
Categories
Pharmaceutical Company
Pharmaceutical Sales
Pharmaceutical
Distributor
Pharmaceutical
Preparation
Pharmaceutical
Jobs
Pharmaceutical
Industry
Pharmaceutical
Drug
Pharmaceutical
Sales Jobs
Pharmaceutical
Product
Pharmaceutical
News
Pharmaceutical
Research
Pharmaceutical
Manufacturer
Pharmaceutical Sales
Rep
Pharmaceutical
Sales Resume
Pharmaceutical
Online
Pharmaceutical
Marketing
Pharmaceutical
Dictionary
Pharmaceutical
Recruiter
Pharmaceutical
Supply
Pharmaceutical
Technology
Pharmaceutical
Advertising
Pharmaceutical
Schools
Companies
Pfizer Pharmaceutical
Wyeth Pharmaceutical
Watson Pharmaceutical
Merck Pharmaceutical
Roche Pharmaceutical
King Pharmaceutical
Teva Pharmaceutical
Aventis
Pharmaceutical
Novartis
Pharmaceutical
Forest
Pharmaceutical
Tap
Pharmaceutical
Shire
Pharmaceutical
Mayne
Pharmaceutical
Millennium
Pharmaceutical
Lilly
Pharmaceutical
Mylan
Pharmaceutical
Kos
Pharmaceutical
Takeda
Pharmaceutical
Endo
Pharmaceutical
Janssen
Pharmaceutical
Barr
Pharmaceutical
Abbott
Pharmaceutical
Reliant
Pharmaceutical
Solvay
Pharmaceutical
Amylin
Pharmaceutical
Vertex
Pharmaceutical
Osi
Pharmaceutical
Bayer
Pharmaceutical
Voyager
Pharmaceutical
Mcneil
Pharmaceutical
Boehringer
Ingelheim
Astra
Zeneca Pharmaceutical
Glaxosmithkline
Pharmaceutical
Novo Nordisk
Pharmaceutical
3m
Pharmaceutical
Eli
Lilly Pharmaceutical
Elan Pharmaceutical
Ivax
Pharmaceutical
Search engines:
Google
Lycos
AltaVista
Yahoo
Mirago
Ask
Teoma
Excite |
|
|
|
Mayne Pharmaceutical
Mayne Pharmaceutical
Mayne
Pharma Limited is focused on the development, manufacture, sale and
distribution of medicines used by oncologists. The company is listed on the
Australian Stock Exchange under the code “MYP”.
Mayne
Pharma’s product portfolio has been built on world class process
development capabilities in the two families of drugs that are commonly used in
the treatment of cancer today: taxanes and platinum derivatives. The company
has also expanded from its origins in generic chemotherapy medicines to related
therapeutic drugs used by oncologists in the treatment of cancer such as
antibiotics and pain management.
On the back of this expertise, Mayne
Pharma has expanded from Australia so that it now distributes its products in
more than 65 countries around the world. It has established strong commercial
footholds especially in Europe and Asia Pacific. In North America, Mayne Pharma
is the second largest supplier of generic, injectable oncology medicines in
Canada and the company has a small and developing position in the United States
that provides future opportunity to grow.
Mayne Pharma has increased
its sales revenues significantly in the last three years on the back of
acquisitions and internal growth. Pro-forma sales in its 2005 financial year
were A$687 million up approximately 35% on the prior year.
In November
2005, Mayne Pharma was demerged from Mayne Group Limited so the business could
focus on its core competencies and have increased flexibility to implement
appropriate strategies and a capital structure that would help facilitate its
continued success.
02/02/07: Hospira
www.hospira.com has announced that it has
completed the acquisition of Mayne Pharma, in the process creating the world's
leading firm in speciality generic injectible pharmaceuticals. According to the
terms of the transaction, the total value for the acquisition is AUD$2.6
billion (1.02 billion pounds), equating to an offer of AUD$4.10 per share to
shareholders in Mayne Pharma. Following this acquisition, Hospira is
implementing a new structure of leadership in order to establish a robust basis
for growth in the future, augment its connection with customers and promote a
stronger global perspective. To these ends, the company has appointed three
regional presidents, two presidents focused on long-term growth and a corporate
vice president of global strategy and business development. Christopher B
Begley, chief executive officer of Hospira, said: "We are excited and confident
about the growth opportunities this acquisition presents for all of our
stakeholders." He added that the increased size of the company would enable it
to reduce the overall costs of healthcare, resulting in an improvement in the
financial strength of the healthcare system worldwide and enhanced
affordability of care for patients. The Supreme Court of Victoria approved the
scheme for the transaction of Mayne Pharma by a subsidiary of Hospira earlier
this month. \
Mayne Pharmaceutical - Research &
development
Mayne Pharma have proven expertise in solving drug
delivery problems for patients and health professionals. Mayne Pharma pride
themselves in being a customer-orientated company by continuing to develop
products and services that meet their customers' needs for innovative drug
delivery. The Mayne Pharma team of more than 200 scientists, chemists and
regulatory affairs specialists are critical to the timely delivery of
innovative new products. With more than US$20 million invested annually in
product development, the Mayne Pharma product pipeline extends beyond five
years and is focused on providing customers with innovation well into the
future. mayne Pharma's drug delivery capabilities focus on developing
innovative products with improved formulations, new dosage forms and simpler
dosing schedules. Mayne Pharma will continue their development of innovative
drug delivery technology, using in-house expertise, combined with collaborative
development programs in association with academic and government research
organisations. To support this vision, Mayne Pharma regularly partner with
suppliers of active pharmaceutical ingredients to meet the challenge of
developing generic pharmaceuticals. Mayne Pharma's global network of
experienced regulatory affairs personnel enables them to achieve regulatory
approvals faster than the pharmaceutical industry average.
Mayne Pharmaceutical -
Manufacturing
Mayne Pharma is focused on developing a globally
competitive supply chain through manufacturing products internally as well as
strategically outsourcing some of its manufacturing requirements to reliable,
high quality contract manufacturers.
Mayne Pharma manufactures
pharmaceutical products in Australia, Germany and Puerto Rico for distribution
to more than 65 countries around the world. Through a joint-venture with Zydus
Cadila, we are also constructing a manufacturing facility in India that will
produce cytotoxic anti-cancer agents when it is complete.
Mayne Pharma
are capable of developing and manufacturing a wide variety of products to meet
the increasingly diverse needs of our stakeholders globally. Mayne Pharma has
the infrastructure and expertise to meet the requirements of each of the major
regulatory authorities and to promptly secure product approvals.
Mayne
Pharma's facilities are world-class and have been approved by the major
authorities, including the FDA (USA), the MCA (United Kingdom), the HPFB
(Canada) and the TGA (Australia).
Mayne Pharma's Mulgrave facility is
its largest and most diverse finished dosage facility, with capabilities to
formulate, fill, label and package finished dosage forms of injectable
pharmaceutical products. Approximately A$50 million has been invested to
establish a new cytotoxic production facility at Mulgrave that is expected to
improve efficiency and be compliant with current Good Manufacturing Practice
(cGMP) requirements. The new facility is expected to begin commercial
production for Australia in 2006, with approvals for overseas markets expected
to follow later in that year.
Mayne Pharma's Wasserburg facility in
Germany can produce both terminally sterilized and aseptically filled ampoules
and vials. The core competency of the business is lyophilization, a complex
technique to freeze-dry a solution into a solid or powder to offer extended
shelf life of the product.
The Aguadilla, Puerto Rico facility is
currently going through an extensive upgrade and is expected to progressively
recommence commercial production from around the middle of calendar year 2006.
The Aguadilla facility will have the capability to formulate, fill, label and
package finished dosage forms of injectable pharmaceutical
products.
Mayne Pharma's joint venture with Zydus Cadila in India will
almost double Mayne Pharma's cytotoxic manufacturing capabilities and assist
with early development and launch of products at patent expiry in key target
markets. The first products produced by the joint venture are expected to be
launched in fiscal year 2008.
www.maynepharma.com |
\ |
|
|
|
